<DOC>
	<DOC>NCT00152464</DOC>
	<brief_summary>The Early Prevention of Asthma in Atopic Children (EPAAC™) . 24 months study to evaluate the efficacy and safety of levocetirizine (LCTZ) in preventing the onset of asthma in 12 to 24 months old children.</brief_summary>
	<brief_title>Prevention of Asthma With Levocetirizine 18 Month Treatment in Infants (12 - 24 Months) Suffering From Eczema (Atopic Dermatitis) and Sensitized to Grass Pollen and/or House Dust Mite (HDM)</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis, Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<mesh_term>Levocetirizine</mesh_term>
	<mesh_term>Cetirizine</mesh_term>
	<criteria>Inclusion criteria which must be verified during screening visit (V1): Children of either sex aged between 12 and 24 months. Subjects suffering from symptoms of Atopic Dermatitis (AD) lasting cumulatively for at least 2 months since birth. Modified SCORAD Index ≥ 10 Subjects whose biological mother or father, or one sibling has a welldocumented history of atopy (AD, allergic rhinitis or asthma). Inclusion criteria which must be verified during randomization (V2): Results of the RAST test for GP and HDM are available and IgE level against GP ≥ 0.35 kUA/l and / or IgE level against HDM ≥ 0.35 kUA/l. Safety laboratory results are within the normal range of the central laboratory or considered as not clinically significant or study disease related by the Investigator. Exclusion criteria to verify at screening visit (V1): Are to be excluded from the participation in the study, those children who Have height or weight below the 5th percentile. Have experienced at least one episode of wheezing when aged 6 months or over. Have suffered at age 6 months or over, from at least one nocturnal cough episode consisting of 3 (or more) consecutive nights resulting in sleep disturbances in a clinical setting where asthma is likely and other conditions have been excluded. Have chronic pulmonary diseases of any type, such as, but not limited to, cystic fibrosis, or any craniofacial abnormality, e.g., cleft palate. Have a personal history of sleep apnea or who have siblings with a history of sleep apnea. Are treated with any immunomodulator medication such as, e.g., cyclosporin, cyclophosphamide or FK 506 (Tacrolimus). Have received or are receiving allergen specific immunotherapy. Suffer from concomitant dermatological disease/condition other than atopic dermatitis, that might interfere with the evaluation of the clinical response for atopic dermatitis. Have an insufficient washout period for the following medications: Intranasal or systemic antihistamines: 3 days, Intranasal or systemic decongestants: 3 days, Loratadine, Desloratadine: 10 days, Chromones: 2 weeks, Oral corticosteroids: 1 month, Chronic use (i.e. cumulatively up to 2 weeks within the last 3 months) of inhaled/intranasal corticosteroids: 1 month, Ketotifen: 1 month, Astemizole: 6 weeks Have been treated with any antihistamine, including ketotifen, with daily intake for more than 2 consecutive months in the last 6 months before screening. Subject Exclusion criteria to verify at randomization visit (V2): • Intake of any prohibited medication listed above during the selection period.</criteria>
	<gender>All</gender>
	<minimum_age>12 Months</minimum_age>
	<maximum_age>24 Months</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>EPAAC , atopic Children, asthma, XYZAL, levocetirizine</keyword>
</DOC>